MiMedx Group, Inc. (NASDAQ:MDXG) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP lessened its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 33.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 199,300 shares of the company's stock after selling 98,400 shares during the quarter. Two Sigma Advisers LP owned about 0.14% of MiMedx Group worth $1,917,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in MDXG. Dimensional Fund Advisors LP raised its holdings in MiMedx Group by 15.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company's stock worth $17,338,000 after purchasing an additional 238,075 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in MiMedx Group during the fourth quarter valued at approximately $450,000. Raymond James Financial Inc. acquired a new stake in MiMedx Group in the fourth quarter worth $887,000. Tower Research Capital LLC TRC grew its holdings in MiMedx Group by 77.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after buying an additional 2,837 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in MiMedx Group by 79.9% during the 4th quarter. SG Americas Securities LLC now owns 83,385 shares of the company's stock valued at $802,000 after purchasing an additional 37,031 shares in the last quarter. Hedge funds and other institutional investors own 79.15% of the company's stock.

MiMedx Group Stock Down 1.2%

MiMedx Group stock traded down $0.08 during midday trading on Friday, reaching $6.47. The stock had a trading volume of 571,892 shares, compared to its average volume of 690,770. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14. The company has a market capitalization of $955.63 million, a P/E ratio of 11.76 and a beta of 1.85. The company has a fifty day moving average price of $6.94 and a two-hundred day moving average price of $8.14. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, meeting the consensus estimate of $0.06. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The business had revenue of $88.21 million for the quarter, compared to the consensus estimate of $86.32 million. As a group, equities analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Insider Activity at MiMedx Group

In other news, CAO William Frank Iv Hulse sold 54,596 shares of MiMedx Group stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $430,762.44. Following the completion of the transaction, the chief accounting officer now directly owns 440,178 shares in the company, valued at approximately $3,473,004.42. This trade represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the transaction, the insider now owns 310,836 shares of the company's stock, valued at $2,452,496.04. The trade was a 1.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 141,907 shares of company stock valued at $1,112,580 over the last 90 days. 1.70% of the stock is owned by insiders.

Analysts Set New Price Targets

MDXG has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a report on Thursday, February 27th. Wall Street Zen lowered MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 9th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.